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Abstract  
Introduction: Friedrich Ataxia’s diagnosis is typically based on clinical 
symptoms and extended GAA repeats. However, in some rare cases the 
disease is caused as a result of the mutation in the exons of the FRDA 
(Friedreich's ataxia) gene. The current study aimed to examine point 
mutations in exon 1 of the FRDA gene with the goal of finding a better way 
for diagnosing people suspected of this disease. 
Materials and Methods: In this study, 30 suspected patients of Friedrich 
Ataxia underwent PCR molecular test. Subsequently, sequencing and long 
PCR were utilized to assess exon 1 in five patients with extended repeats. 
Results: In total, 25 participants who had extended repeats were diagnosed 
with Friedrich Ataxia. In one out of the five patients, the nucleotide change 
from G to T was observed in the nucleotide number 815324. 
Conclusion: Since the change had a heterozygous nature, it did not cause 
any deficiency in Frataxin protein. Given that family marriages are prevalent 
in Iran, there is a possibility of homozygosity with this mutation or other 
mutations. It is thus recommended that gene sequencing should be performed 
for individuals with suspected Friedrich Ataxia. 
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1. Introduction 
     Friedrich Ataxia (FA) is the most 
common type of Ataxia which is inherited 
as autosomal recessive. Reduction of 
Frataxin, which is a mitochondrial protein, 
leads to the clinical and pathological 
manifestation of this disease [1-3]. 
Normally, 1 in 5000 people suffers from 
this disease. In some societies with a lot of 
family marriages, the prevalence of this 
disease is even higher. Whites are more 
vulnerable to FA, while males and females 
are equally susceptible to it. The first 
symptoms of this disease are usually 
manifested between 5 to 15 years of age, 
with some early and late manifestations 
being respectively reported at ages of 18 
months and 30 years. Through progressive 
degeneration of the sensory nerves, the 
disease eventually leads to weakness and 
disabilities. The most common cause of 
death among FA patients is heart failure [4, 
5]. 
In most cases, the molecular cause of FA is 
the extension of GAA repeats (more than 30 
repeats) in intron 1 of both alleles of FXN. 
The extended repeats hinder gene 
transcription, hence causing deficiency in 
Frataxin. The gene defining FRDA or FXN 
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Frataxin is located in chromosome 9q13, 
with a length of 80 kbp and 7 exons [6, 7].  
As already mentioned, in most of the cases, 
FA is caused by mutation in the extension 
of homozygous tri nucleotide repeats. 
However, in some patients, FA is caused by 
the extension of triple repeats in a single 
allele and point mutation in the other one [8, 
9]. The absence of homozygous genotypes 
for point mutations may be due to the low 
occurrence of these mutations [10,11]. 
Considering molecular diagnosis, there are 
around 33 repeats in the PCR product band 
of normal people. In patients, however, the 
band length goes up, with the extended 
bands being confirmed only by Long PCR. 
Regarding people with 500 bp bands and 
FA symptoms, two scenarios are possible: 
first, such people are not infected by FA, 
meaning that they should undergo other 
diagnostic tests that are used for patients 
with diseases that have phenotypic 
similarity to this disease. The second 
possibility is that such people have an 
extended GAA allele and a point mutation 
in the second allele. That is, they are 
compound heterozygote. Given that the 
majority of reported mutations have 
occurred in exon 1 and that family 
marriages are common in Iran, the current 
study examined exon 1 among people with 
FA symptoms and 500 bp bands to 
investigate point mutations. 
 
2. Materials and Methods 
2.1 Study Design and Patients  
     Thirty people (18 males and 12 females) 
suspected of FA, who had referred to 
Tehran Special Diseases Center, were 
selected for the study. These participants 
had FA phenotypic features (including 
muscle weakness, imbalance, and speech 
impairment). Written informed consent was 






2.2 DNA Extraction 
     QIAGEN kit was used to extract DNA 
from the blood of the 30 patients who were 
suspected of FA. 
 
2.3 PCR for Intron 1 of FRDA Gene 
     After extracting DNA, for intron1 of 
FRDA gene amplification, PCR was carried 
out using DNA thermal cyclers and GAA-F 
and GAA-R primers in 25 µl of a solution 
containing 2.5 µl of buffer, 0.5 µl of 
MgCl2, 0.5 µl of dNTP, 0.5µl of each 
primer, 2 µl of DNA and 0.5µl Taq DNA 
polymerase (Ependorf Master Cycler 
Gradiant).  The PCR reaction was 
performed for 30 cycles composed of the 
following steps: 95 ºC for 5 min, 94 ºC for 
45˝, 64 ºC for 30˝, 72 ºC for 2 min and 72 
ºC for 10 min. In order to assess test 
reliability, both negative control (without 
the disease) and positive control (with the 
disease) samples were used. The 
oligonucleotides used as specific primers 





2.4 PCR for Exon 1 of FRDA Gene 
     For exon 1 of FRDA gene amplification, 
PCR was carried out, using DNA thermal 
cyclers and F and R primers in 25 µl of a 
solution containing 2.5 µl of buffer, 0.5 µl 
of MgCl2, 0.5 µl of dNTP, 0.5µl of each 
primer, 2 µl of DNA 5 µl of DMSO, and 
0.5µl Taq DNA polymerase. (Eppendorf 
Master Cycler Gradiant).  The PCR reaction 
was performed for 30 cycles composed of 
the following steps: 94 ºC for 5 min, 94 ºC 
for 50˝, 68 ºC for 50˝, 72 ºC for 35 ˝ and 72 
ºC for 1 min. The oligonucleotides used as 
specific primers for gene were as follows:  






 Novel Mutation in FRDA Gene, Mousavi Niri N et al.      
 
 Archives of Advances in Biosciences is an open access article under the terms of the Creative Commons Attribution -NonCommercial 4.0 International License,  
32 
2.5 Long PCR 
     While studying the sequence of FXN 
exons for exon 1, heterozygous mutation 
was observed in one of the patients. Based 
on the patient’s phenotype and mutation 
observed in the gene, it was hypothesized 
that the patient was an abnormal case of 
FA; that is, he had point mutation in one 
allele and extended GAA repeats in the 
other, which could not be detected by PCR; 
therefore, Long PCR was done. For this 
PCR using DNA thermal cyclers Bam r and 
2500f primers and two solutions that 
solution 1 containing 7.9 µl of Dd H2O, 0.5 
µl of dNTP Mix 10mM, 0.8 µl of each 
primer, 2 µl of DNA and solution 2 
containing 8 µl of Dd H2O, 2.5 µl of 
Expand Buffer without MgCl2, 1.6 µl of 
MgCl2 25mM and 0.4 µl of Expand 
Enzyme (1 and 2 kit solutions of expand 
high fidelity PCR system of Roche). The 
PCR reaction was performed for 20 cycles 
composed of the following steps: 94 ºC for 
5 min, 94 ºC for 20˝, 68 ºC for 2.5 min and 
17 cycles composed of the following steps: 
94 ºC for 20˝, 68 ºC for 2.5 min MWG 
Biotech Inc Primus 25 Thermal Cycler, 110 
VAC). The oligonucleotides used as 
specific primers for gene were as follows: 
F: caatccaggacagtcagggcttt. R: 
ggmagggatccgtctgggcaaagg. 
2.6 Electrophoresis  
     In order to make sure about the 
duplication of the specific components of 
each gene and the absence of non-specific 
products and dimmer primer, 5 μl of the 
PCR product was loaded on 1.5% agarose 
gel and electrophoresed for 30 minutes. 




     Upon sequencing PCR samples (Kosar 
Kavosh Fanavaran Company, ABI 3700), 
Finch TV was used for reading the 
sequence. Then, NCBI website was 
consulted to compare the results for the 
obtained sequence with normal ones. 
 
3. Results 
     No band was obtained for 25 patients. 
Thus, they were diagnosed with FA. The 
results of Long PCR for this patient 
indicated that the other allele of this gene 
had a band of 1380 bp. In one of the five 
heterozygous patients with 500 bp band, 




Figure 1. DNA bands extracted by QIAGEN kits, Ladder 100. 
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Figure 2. From left to right: 1. Ladder 50, PCR Product of intron 1: 2. 500 bp band, 3. Positive control, 4. No band was 




Figure 3.  PCR Product of exon 1(240 bp ), Ladder100 bp. 
 
 
Figure 4. From left to right: Ladder 1kb, Long PCR Product of intron 1(1380 bp). 
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Figure 5. The nucleotide change from G to T was observed in the nucleotide number 815324. 
 
4. Discussion 
     It is important to conduct molecular 
investigation of FA, given that phenotypic 
features are common in most of the 
neurological diseases. It is therefore 
difficult to diagnose FA solely based on 
clinical features [12]. The most common 
type of mutation which is observed in over 
98% of patients with FRDA is the extension 
of three repeats GAA in the intron of FXN. 
About 5% of people who suffer from FRDA 
are compound heterozygous, consisting of 
disease-making GAA extension in one 
allele and disabling mutation of FXN in the 
other [13]. In molecular diagnosis of this 
disease, if normal band is obtained from 
PCR product, diagnosis tests that are used 
for similar diseases will be exploited for the 
patients based on their phenotypic 
symptoms. Nevertheless, it is likely that a 
particular patient suffers from an abnormal 
case of FRDA (which happens in 5% of the 
cases). In such cases, due to the extension 
of GAA repeats, band length increase in one 
allele, no band is observed in the normal 
PCR, and the normal band has point 
mutation (500 bp band). In this study, in 
order to diagnose patients, intron 1 was 
reproduced using GAA-F and GAA-R 
primers. All in all, 25 patients were 
diagnosed with FA because they had 
extended repeats. In some patients (5%), FA 
is caused by factors such as deletion of few 
nucleotides [13,14] point mutations [14, 
15,16] deletion-insertion mutations [17], 
deletion of complete exons [15, 18], and 
complete deletion of FRDA [19]. In such 
cases, most of the reported mutations occur 
in exon 1. Thus, in the 5 patients with no 
observed extended band, exon 1 was 
sequenced to study the relationship between 
point mutations and infection with FA. 
Similar attempts have already been made. 
For example, guanine nucleotide has 
changed to thymine in exon 1, which causes 
deficiency in protein translation; guanine 
nucleotide has been deleted in exon 1, a 
change that causes deficiency at the end of 
Frataxin translation (100delG); cytosine 
nucleotide has been deleted in exon 1, 
which leads to early termination of Frataxin 
translation (104delC) [20]; adenine 
nucleotide has changed to guanine in intron 
1, which causes deficiency in termination of 
Frataxin translation (Splice Donor) [21]; 
adenine nucleotide has changed to cytosine 
and thymine nucleotide has changed to 
cytosine in exon 1, leading to deficiency in 
starting the translation; cytosine nucleotide 
has been deleted in exon 1, which leads to 
deficiency at the end of Frataxin translation 
(158delC) [22]; guanine nucleotide has 
changed to adenine in exon 1, which leads 
to early termination of Frataxin translation 
(M1I) [23]; cytosine nucleotide has been 
deleted in exon 1, which causes deficiency 
at the termination of Frataxin translation 
(118delC) [24]; guanine nucleotide has been 
converted to cytosine in intron 1, which 
causes deficiency in termination of Frataxin 
translation (Splice Donor) [25]. Likewise, 
three point mutations found that c.241T>G 
in exon 2 , c.574A>T in exon 5 and 
c.367T>G in exon 3 in patients 
heterozygous for the GAA repeat expansion 
[26]. In another study, exons 1, 2, 3, 4, 5b, 
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and 5a were investigated among patients. 
Several polymorphisms were observed; in 
exon 1, homozygote nucleotide A changed 
to nucleotide G number 815284. That is, 
CCA codon was converted to CCG codon. 
Both of these codons have to do with 
proline amino acid. In the intron region of 
exon 2, homozygote nucleotide C changed 
to G number 825954. In the intron region of 
exon 3, nucleotide T (which was in the form 
of homozygote in some participants and 
heterozygote in others) changed to C 
number 832729. In exon 4, no heterozygote 
or homozygote mutation was observed. 
Among the patients, nucleotide G number 
852225 was added in exon 5a. No 
heterozygote or homozygote mutation was 
observed in exon 5b [27, 28]. In the current 
study, in exon 1 in one of the patients, a 
heterozygote mutation was observed, in 
that, nucleotide G changed to nucleotide T. 
In other words, GAG codon was converted 
to TAG codon, in homozygote mutation the 
codon that is related to glutaric acid is 
converted to stop codon. 
 
5. Conclusion 
     Given that heterozygote mutation was 
observed, this type of change does not lead 
to Frataxin deficiency. Based on the 
phenotypic symptoms of the FA patients, it 
is hypothesized that mutation has occurred 
in areas other than the studied ones (e.g. the 
promoter region of this gene). Since family 
marriages are dominant in Iran, it is highly 
likely that homozygote children with this 
mutation or other mutations are born. It is 
therefore necessary to conduct gene 
sequencing in diagnosing patients who are 
suspected of FA.  
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